NASDAQ$NBP

NovaBridge Biosciences · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Headline financials

Total Revenue

$17.8M

No prior period
EPS (adj)

-$6.38

Previous: -$0.78-718.7%
Capital Expenditures

$4.06M

No prior period
Free Cash Flow

-$447M

No prior period
Net Income

-$538M

Previous: -$291M-84.7%
Gross Profit

$8.89M

Previous: $0.00
Cash & Equivalents

$4.35B

No prior period
Stock-Based Comp

$335M

No prior period

Revenue & EPS history

I-Mab · Revenue · Quarterly

$17.8M

Q2 2021
Beat estimate in 3 of 4 quarters(75%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 12 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

+5.1%

Avg return

Earnings day

+4.3%

Avg return

5 days after

+9.7%

Avg return

30 days after

54%

7 / 13 earnings

Positive

+17.2%

Q2 2022

Best reaction

-7.7%

Q3 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2023+0.0%-1.1%
Q4 2022-4.2%-1.6%+0.6%
Q2 2021+17.2%+34.6%+13.3%
Q2 2022+17.2%+34.6%+13.3%
Q4 2021+7.0%+7.1%-35.6%
Q1 2022+12.5%+3.9%-23.7%
Q4 2020-6.9%-3.6%+25.8%
Q3 2021-7.7%-8.2%-21.5%
Q3 2020-7.7%-8.2%-21.5%
Q2 2020-0.9%-8.8%-4.5%
Q4 2017+13.2%+2.4%+56.8%
Q4 2019+13.2%+2.4%+56.8%
Q4 2018+13.2%+2.4%+56.8%
Q2 2019
Q1 2019
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro